¶ Ology Bioservices
.png)
Ology Bioservices (previously Nanocoat Technologies and then Nanotherapeutics) is an American biopharmaceutical company based in Alchua, Florida. It is a subsidiary of National Resilience.
¶ History
The company was founded in 2000 as Nanocoat Technologies by James Talton within the Sid Martin Biotechnology Incubator at the University of Florida. The company changed its name to Nanotherapeutics in 2002.[1]
In 2013, Nanotherapeutics was awarded an Advanced Development & Manufacturing (ADM) contract from the United States Department of Defense (DoD).[1:1]
In December 2014, Baxter International announced it would sell its Vero cell-based vaccine technology to Nanotherapeutics, including a production facility in Bohumil, Czech Republic. The sale included "all assets related to the Vero platform, including vaccines for H5N1, H1N1, and seasonal influenza," as well as "investigational vaccine programs for Ross River virus, Chikungunya disease, and West Nile virus."[2]
Nanotherapeutics was co-signatory to a letter dated July 29, 2015 from the Alliance for Biosecurity to U.S. Representatives Susan Brooks and Anna Eshoo in support of the Strengthening Public Health Emergency Response Act of 2015, which “would support preparedness for potential public health emergencies by increasing accountability and streamlining the contracting process for medical countermeasures (MCMs).”[3]
In October 2017, the company changed its name to Ology Bioservices.[4]
¶ COVID-19
Ology was awarded a contract in February 2020 from the Natick Contracting Division of the United States Army Contracting Command to develop an advanced monoclonal antibody therapy against COVID-19.[5]
In April 2021, Ology Bioservices was acquired by National Resilience.[6]
¶ Organization
The company has been listed as a member of the Alliance for Biosecurity,[3:1] and is a member of the Medical CBRN Defense Consortium.[7]
¶ External links
Clark, A. (2013, March 22). Alachua company lands DOD contract worth up to $360M. The Gainesville Sun. https://web.archive.org/web/20130326025038/http://www.gainesville.com/article/20130322/articles/130329813 ↩︎ ↩︎
Baxter Sells Vero Cell Vaccines Platform to Nanotherapeutics. (2014, December 15). Genetic Engineering & Biotechnology News. http://archive.today/2021.04.19-024757/https://www.genengnews.com/topics/drug-discovery/baxter-sells-vero-cell-vaccines-platform-to-nanotherapeutics/ ↩︎
Alliance for Biosecurity. (2015). Letter to the Honorable Susan Brooks and the Honorable Anna Eshoo (p. 1). U.S. House of Representatives. https://web.archive.org/web/20201217003542/https://docs.house.gov/meetings/IF/IF14/20160519/104953/HHRG-114-IF14-20160519-SD003.pdf ↩︎ ↩︎
Molony, L., & Carey, M. A. (2017, October 2). Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company’s Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics. Business Wire. http://archive.today/2023.02.25-180137/https://www.businesswire.com/news/home/20171002005452/en/Nanotherapeutics-Announces-Name-Change-to-Ology-Bioservices-Reflecting-the-Company’s-Ongoing-Transformation-into-One-of-the-Top-Contract-Development-and-Manufacturing-Organizations-of-Vaccines-and-Biologics ↩︎
MABS Manufacturing Platform Development Agreement with Ology - W911QY-20-9-0003. (2020, February 21). United States Department of Health and Human Services; Natick Contracting Division. https://web.archive.org/web/20230119152656/https://www.hhs.gov/sites/default/files/mabs-manufacturing-platform-development-agreement-with-ology.pdf ↩︎
Sterling, J. (2021, April 13). Resilience Acquires Ology Bioservices. GEN - Genetic Engineering and Biotechnology News. http://archive.today/2022.10.29-181010/https://www.genengnews.com/topics/bioprocessing/resilience-acquires-ology-bioservices/ ↩︎
Current Members. MCDC. Retrieved January 3, 2023, from http://archive.today/2023.01.03-195328/https://www.medcbrn.org/current-members/ ↩︎